机构持仓方面，截止2025年6月30日，华润三九十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股4361.40万股，相比上期增加705.16万股。华泰柏瑞沪深300ETF（510300）位居第四大流 通股东，持股1193.47万股，相比上期增加356.72万股。易方达沪深300医药ETF（512010）位居第五大 流通股东，持股1096.93万股，相比上期增加185.89万股。易方达沪深300ETF（510310）位居第七大流 通股东，持股848.71万股，相比上期增加261.73万股。中欧医疗健康混合A（003095）退出十大流通股 东之列。 华润三九所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：维生素、禽流感药物、医药 电商、抗流感、化妆品等。 截至9月20日，华润三九股东户数10.04万，较上期增加6.25%；人均流通股16561股，较上期减少 5.88%。2025年1月-6月，华润三九实现营业收入148.10亿元，同比增长4.99%；归母净利润18.15亿元， 同比减少24.31%。 分红方面，华润三九A股上市后累计派现100.69亿元。近三年，累计派现49.15亿元。 1 ...

10月9日，吉林敖东盘中上涨2.15%，截至10:58，报20.44元/股，成交2.92亿元，换手率1.23%，总市值 244.44亿元。 资金流向方面，主力资金净流入823.28万元，特大单买入1466.16万元，占比5.02%，卖出1931.71万元， 占比6.62%；大单买入7803.29万元，占比26.73%，卖出6514.46万元，占比22.31%。 吉林敖东今年以来股价涨20.41%，近5个交易日涨7.07%，近20日涨7.07%，近60日涨19.88%。 分红方面，吉林敖东A股上市后累计派现44.30亿元。近三年，累计派现16.47亿元。 机构持仓方面，截止2025年6月30日，吉林敖东十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股1501.38万股，相比上期增加461.49万股。南方中证500ETF（510500）位居第五大流通股 东，持股1424.79万股，相比上期增加191.48万股。汇添富中证中药ETF（560080）位居第十大流通股 东，持股440.92万股，相比上期减少48.30万股。 责任编辑：小浪快报 资料显示，吉林敖东药业集团股份有限公司位于吉林省敦化市敖东大街 ...

Core Viewpoint - The stock of Anglikang has shown significant volatility, with a year-to-date increase of 192.23%, but recent declines in the short term raise questions about future performance [1][2]. Company Overview - Anglikang Pharmaceutical Co., Ltd. is located in Shengzhou, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018. The company focuses on the research, production, and sales of chemical raw materials and formulations [1]. - The main revenue composition includes formulations (43.46%), raw materials (39.82%), specialty intermediates (12.44%), others (3.72%), and pharmaceutical excipients (0.56%) [1]. Financial Performance - For the first half of 2025, Anglikang reported operating revenue of 724 million yuan, a year-on-year decrease of 14.52%, and a net profit attributable to shareholders of 65.93 million yuan, down 3.19% year-on-year [2]. - Since its A-share listing, Anglikang has distributed a total of 341 million yuan in dividends, with 108 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 50.49% to 18,500, with an average of 10,037 circulating shares per person, a decrease of 33.55% [2]. - Notable new institutional shareholders include China Europe Medical Health Mixed A, holding 6.44 million shares, and Guangfa Technology Innovation Mixed A, holding 6.16 million shares [3].

Group 1 - The military equipment restructuring concept declined by 0.52%, ranking among the top declines in the concept sector, with companies like Changcheng Military Industry, Hunan Tianyan, and Zhongguang Optical leading the declines [1][1][1] - The top gainers in today's concept sectors included zinc metal (+3.68%), nickel metal (+3.65%), and lead metal (+3.61%), while the pork sector saw a decline of -0.54% [1][1][1] - The military equipment restructuring sector experienced a net outflow of 263 million yuan, with Changcheng Military Industry seeing the largest outflow of 117 million yuan [1][1][1] Group 2 - The top stocks with net outflows in the military equipment restructuring sector included Changcheng Military Industry (-1.20%), Chang'an Automobile (-0.81%), and Construction Industry (-0.51%) [1][1][1] - Conversely, Hunan Tianyan and Huqiang Technology were among the stocks with net inflows, receiving 2.47 million yuan and 222,100 yuan respectively [1][1][1] - The trading volume for Changcheng Military Industry was 4.97%, while Hunan Tianyan had a turnover rate of 2.32% [1][1][1]

Core Viewpoint - Zhejiang Medicine's stock price has shown a decline of 7.58% year-to-date, with a recent increase of 2.07% on September 24, 2023, indicating potential volatility in the market [1]. Financial Performance - For the first half of 2025, Zhejiang Medicine reported a revenue of 4.323 billion yuan, a year-on-year decrease of 1.87%, while the net profit attributable to shareholders was 673 million yuan, reflecting a significant increase of 113.52% [2]. - Cumulative cash dividends since the company's A-share listing amount to 4.377 billion yuan, with 661 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 65,500, with an average of 14,674 circulating shares per person, a decrease of 0.55% [2]. - The top circulating shareholder, Hong Kong Central Clearing Limited, holds 71.2904 million shares, an increase of 34.9417 million shares compared to the previous period [3].

Core Viewpoint - The stock of Anglikang has shown significant volatility, with a year-to-date increase of 200.05%, but recent declines in the last five, twenty, and sixty trading days indicate potential market concerns [1][2]. Company Overview - Anglikang Pharmaceutical Co., Ltd. is located in Shengzhou, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018. The company specializes in the research, production, and sales of chemical raw materials and formulations [1]. - The main revenue composition of Anglikang includes formulations (43.46%), raw materials (39.82%), specialty intermediates (12.44%), others (3.72%), and pharmaceutical excipients (0.56%) [1]. Financial Performance - For the first half of 2025, Anglikang reported operating revenue of 724 million yuan, a year-on-year decrease of 14.52%, and a net profit attributable to shareholders of 65.93 million yuan, down 3.19% year-on-year [2]. - Since its A-share listing, Anglikang has distributed a total of 341 million yuan in dividends, with 108 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, Anglikang had 18,500 shareholders, an increase of 50.49% from the previous period, with an average of 10,037 circulating shares per person, a decrease of 33.55% [2]. - Notable new institutional shareholders include China Europe Medical Health Mixed A, holding 6.44 million shares, and Guangfa Technology Innovation Mixed A, holding 6.16 million shares [3].

Company Overview - Tongrentang's stock price decreased by 2.01% on September 23, trading at 11.70 CNY per share with a market capitalization of 19.793 billion CNY [1] - The company specializes in the research, production, and sales of dietary nutritional supplements, with revenue composition as follows: Others 38.02%, Capsules 27.84%, Tablets 20.38%, Powders 13.76% [1] Financial Performance - For the first half of 2025, Tongrentang reported a revenue of 3.532 billion CNY, a year-on-year decrease of 23.43%, and a net profit attributable to shareholders of 737 million CNY, down 17.34% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 8.321 billion CNY, with 2.429 billion CNY distributed over the last three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 4.96% to 71,200, while the average circulating shares per person increased by 5.22% to 15,869 shares [2] - Major shareholders include E Fund's ChiNext ETF, holding 24.5972 million shares, a decrease of 648,400 shares from the previous period [3]

Core Viewpoint - The stock of Zhendong Pharmaceutical has experienced fluctuations, with a year-to-date increase of 67.82%, but recent declines in the short term raise concerns about its performance [1][2]. Group 1: Stock Performance - On September 23, Zhendong Pharmaceutical's stock fell by 2.03%, trading at 7.25 CNY per share, with a total market capitalization of 7.289 billion CNY [1]. - The stock has seen a net outflow of 6.7912 million CNY in principal funds, with significant selling pressure in the last trading session [1]. - Year-to-date, the stock has increased by 67.82%, but it has declined by 3.85% over the last five trading days and 23.28% over the last 20 days [1]. Group 2: Company Overview - Zhendong Pharmaceutical, established on November 15, 1995, and listed on January 7, 2011, is located in Changzhi, Shanxi Province [2]. - The company specializes in the research, production, and sales of generic and innovative drugs across various therapeutic areas, including oncology and urology [2]. - The revenue composition includes 54.82% from traditional Chinese medicine, 43.10% from chemical drugs, and 1.98% from other sources [2]. Group 3: Financial Performance - For the first half of 2025, Zhendong Pharmaceutical reported a revenue of 1.457 billion CNY, a year-on-year decrease of 3.30%, and a net profit attributable to shareholders of 7.9313 million CNY, down 74.13% year-on-year [2]. - The company has distributed a total of 3.372 billion CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]. - As of June 30, 2025, the number of shareholders decreased by 5.04% to 46,100, while the average circulating shares per person increased by 5.31% to 21,777 shares [2].

Company Overview - Hongyang Sun is located in Nanjing, Jiangsu Province, established on June 13, 1991, and listed on October 28, 1993. The company specializes in the research and production of new environmentally friendly pesticides, with pesticide sales accounting for 96.95% of its main business revenue [1][2]. Stock Performance - On September 22, Hongyang Sun's stock price decreased by 2.13%, reaching 6.42 CNY per share, with a trading volume of 66.64 million CNY and a turnover rate of 1.04%. The total market capitalization is 8.33 billion CNY [1]. - Year-to-date, the stock price has increased by 7.54%, but it has seen declines of 3.17% over the last five trading days, 8.02% over the last 20 days, and 13.48% over the last 60 days [1]. Capital Flow - There was a net outflow of 11.49 million CNY from main funds, with no large orders bought and 3.54 million CNY sold, accounting for 5.31%. Large orders bought totaled 10.96 million CNY (16.45%), while large orders sold reached 18.92 million CNY (28.39%) [1]. Financial Performance - For the period from January to June 2025, Hongyang Sun reported a revenue of 1.46 billion CNY, a year-on-year decrease of 11.08%. The net profit attributable to the parent company was -208 million CNY, a significant decline of 1081.73% [2]. - Since its A-share listing, the company has distributed a total of 1.146 billion CNY in dividends, with no dividends paid in the last three years [2]. Shareholder Information - As of August 29, the number of shareholders for Hongyang Sun was 47,400, an increase of 3.92% from the previous period. The average number of circulating shares per person is 20,892, which is a decrease of 3.77% [2].

Core Viewpoint - Huadong Medicine's stock price has shown volatility, with a year-to-date increase of 23.26% but a recent decline in the last five and twenty trading days [1] Financial Performance - For the first half of 2025, Huadong Medicine achieved a revenue of 21.675 billion yuan, representing a year-on-year growth of 3.39% [2] - The net profit attributable to shareholders for the same period was 1.815 billion yuan, reflecting a year-on-year increase of 7.01% [2] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 7.91% to 69,800, while the average circulating shares per person increased by 8.59% to 25,083 shares [2] - Cumulative cash dividends since the A-share listing amount to 8.873 billion yuan, with 3.771 billion yuan distributed in the last three years [3] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited is the third-largest circulating shareholder with 39.8384 million shares, a decrease of 6.2825 million shares from the previous period [3] - The top ten circulating shareholders include various funds, with notable changes in holdings among them, such as an increase in shares held by China Europe Medical Health Mixed A and a decrease by E Fund CSI 300 Medicine ETF [3] Business Overview - Huadong Medicine, established on March 31, 1993, and listed on January 27, 2000, operates primarily in the production and sales of pharmaceutical products, with a revenue composition of 64.45% from commercial activities and 39.69% from manufacturing [1] - The company is involved in various sectors, including vitamins, pharmaceutical e-commerce, vaccine transportation, peptide drugs, and hepatitis treatment [1]